Developing novel immunogens for an effective, safe Alzheimer's disease vaccine

Neurodegenerative Diseases

Volumn 2, Issue 5, 2006, Pages 267-272

  Maier, Marcel ^a   Seabrook, Timothy J ^a   Lemere, Cynthia A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Center for Neurologic Diseases   (United States)

Author keywords

A immunization; Alzheimer's disease; B cells; Immunotherapy; T cells

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-30]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-5]; AMYLOID BETA PROTEIN[15-24]; AMYLOID BETA PROTEIN[3-9]; AMYLOID BETA PROTEIN[5-11]; AMYLOID BETA PROTEIN[5-1]; AMYLOID PRECURSOR PROTEIN; ANTIGEN; ARGINYLGLYCYLASPARTIC ACID; B LYMPHOCYTE ANTIGEN; BOVINE SERUM ALBUMIN; ENTEROTOXIN; EPITOPE; PERTUSSIS TOXIN; POLYSORBATE 80; QS 21; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLEEDING; CELLULAR IMMUNITY; CLINICAL TRIAL; COGNITION; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; ENCEPHALITIS; EXPERIMENTAL ANIMAL; GLIOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLAMMATION; MALARIA; MENINGOENCEPHALITIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; WILD TYPE;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; CLINICAL TRIALS; EPITOPES; HUMANS; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; TANDEM REPEAT SEQUENCES;

EID: 33646062007     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000090367     Document Type: Review

References (48)

1. Selkoe D: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
2. Wilquet V, De Strooper B: Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 2004;14:582-588.
3. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
4. Walsh DM, Selkoe DJ: Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004;11:213-228.
5. Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44:181-193.
6. Small G, Rabins P, Barry P, Buckholtz N, DeKosky S, Ferris S, Kinkel S, Gwyther L, Khachaturian Z, Lebowitz B, McRae T, Morris J, Oakley F, Schneider L, Streim J, Sunderland T, Teri L, Tune L: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.
7. Walker LC, Ibegbu CC, Todd CW, Robinson HL, Jucker M, LeVine H 3rd, Gandy S: Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochem Pharmacol 2005;69:1001-1008.
8. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vendevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
9. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985.
10. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
11. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.
12. DeMattos R, Bales K, Cummins D, Dodart JC, Paul S, Holtzman D: Peripheral anti-Aβ antibody alters CNS and plasma clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
13. Dodart J-C, Bales K, Gannon K, Greene S, DeMattos R, Mathis C, DeLong C, Wu S, Wu X, Holtzman D, Paul S: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nature Neurosci 2002;5:452-457.
14. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T: Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003;100:2023-2028.
15. Frenkel D, Katz O, Solomon B: Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA 2000;97:11455-11459.
16. Lemere C, Spooner E, LaFrancois J, Malester B, Mori C, Leverone J, Matsuoka Y, DeMattos R, Holtzman D, Clements J, Selkoe D, Duff K: Evidence for peripheral clearance of Aβ following chronic,active Aβ immunization in PSAPP mice. Neurobiol Dis 2003;14:10-18.
17. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ: Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005;11:556-561.
18. Nicoll J, Wilkinson D, Holmes C, Steart P, Markham H, Weller R: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-452.
19. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129-131.
20. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20.
21. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54.
22. Pride MW, Black RS, Hagen M, Dispoto S, Souza V, Giorgio D, Jenkins L, Johnson-Fenno L, Ginsberg R, Daniels M, Koller M, Eldridge J: Evaluation of the cellular immune response in AD patients after immunotherapy with AN1792(QS-21). Poster No. 201.14. 33rd Annu Meet Soc Neurosci, New Orleans, November, 2003.
23. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
24. Cribbs D, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman C, Agadjanyan M: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003;15:505-514.
25. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G: Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 2003;126:285-291.
26. DeMattos R, Bales K, Cummins D, Paul S, Holtzman D: Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264-2267.
27. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews P, Jucker M: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002;298:1379.
28. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-636.
29. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D: Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004;1:24.
30. Lee EB, Leng LZ, Lee VMY, Trojanowski JQ: Meningoencephalitis associated with passive immunization of a transgenic murin model of Alzheimer's amyloidosis. FEBS Lett 2005;579:2564-2568.
31. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ: Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci 2000;920:328-331.
32. Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M: Characterization of murine immunoglobulin G antibodies against human amyloid-β1-42. Neurosci Lett 2001;307:101-104.
33. McLaurin J, Cecal R, Kierstead M, Tian X, Phinney A, Manea M, French J, Lambermon M, Darabie A, Brown M, Janus C, Chishti M, Horne P, Westaway D, Fraser P, Mount H, Przybylski M, St George-Hyslop P: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-1269.
34. Seabrook TJ, Iglesias M, Bloom JK, Spooner ET, Lemere CA: Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice. Vaccine 2004;22:4075-4083.
35. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR: Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004;165:283-297.
36. Monsonego A, Zota V, Kami A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003;112:415-422.
37. Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL: Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:10273-10278.
38. Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA: Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for 'boosting'. Vaccine 2003;21:2197-2206.
39. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH: Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005;174:1580-1586.
40. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T: Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001;159:439-447.
41. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T: An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 2004;24:6277-6282.
42. Calvo-Calle JM, de Oliveira GA, Clavijo P, Maracic M, Tam JP, Lu YA, Nardin EH, Nussenzweig RS, Cochrane AH: Immunogenicity of multiple antigen peptides containing B and non-repeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum. J Immunol 1993;150:1403-1412.
43. Ahlborg N, Andersson R, Perlmann P, Berzins K: Immune responses in congenic mice to multiple antigen peptides based on defined epitopes from the malaria antigen Pf332. Immunology 1996;88:630-635.
44. Hewer R, Meyer D: Peptide immunogens designed to enhance immune responses against human immunodeficiency virus (HIV) mutant strains: a plausible means of preventing viral persistence. J Theor Biol 2005;233:85-90.
45. Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA: Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005;54:107-119.
46. Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD: Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 2002;23:991-1000.
47. Oishi Y, Onozuka A, Kato H, Shimura N, Imai S, Nisizawa T: The effect of amino acid spacers on the antigenicity of dimeric peptide - inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans. Oral Microbiol Immunol 2001;16:40-44.
48. Yano A, Onozuka A, Matin K, Imai S, Kanada N, Nisizawa T: RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunization. Vaccine 2003;22:237-243.